Premaitha passes regulator's test
Genetic analysis specialist Premaitha Health (NIPT:AIM) has cleared its first hurdle since IPO'ing 4 July 2014 at 11p per share, but greater challenges await. Securing clearance to sell its highly accurate pre-natal diagnostic...
05 February 2015
